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 TITLE PAGE 1 
Title: Treatment Response Mapping to quantify regional ventilation changes in the lung using 2 
hyperpolarized gas MRI 3 
Manuscript type: 2607 words  4 
Advance in Knowledge:  5 
-Treatment Response Mapping (TRM) is a novel technique for quantitative assessment of regional 6 
lung ventilation changes in response to treatment. 7 
- The net TRM integrated over the whole lungs (ǻRnet) correlates with changes in spirometry 8 
(3HDUVRQ¶VFRUUHODWLRQǻFEV1: r = 0.70, ǻFVC: r = 0.84; p<0.01).  9 
-In comparison to standard clinical outcome measures based on lung function, TRM adds 10 
information about the size and direction of the regional physiological response of the lungs.  11 
Implication for Patient Care:  12 
-Treatment Response Mapping (TRM) has potential for the assessment of regional lung 13 
interventions such as anti-inflammatory therapies or targeted therapies such as thermoplasty, 14 
endobronchial valve therapy and lung volume reduction surgery. 15 
-Potential clinical applications for TRM are paediatric and longitudinal studies of lung disease 16 
progression as patients are not exposed to ionizing radiation.  17 
Summary Statement:  18 
Treatment Response Mapping (TRM) is introduced as a novel technique to provide regional 19 
quantitative information on changes in lung ventilation in response to therapy and is 20 
demonstrated in an asthma cohort by measuring bronchodilator response.   21 
 Abstract (248 words) 22 
Purpose: To assess the magnitude of regional response to respiratory therapeutics in the lungs 23 
using Treatment Response Mapping (TRM) with hyperpolarized gas MRI. TRM is used to quantify 24 
regional physiological response in asthmatic adults using a bronchodilator challenge. 25 
Methods: The study was approved by the national research ethics committee and performed with 26 
informed consent. Imaging was performed in 20 adult asthmatic patients using hyperpolarized 3He 27 
ventilation MRI. Two sets of baseline images were acquired before inhalation of a bronchodilator 28 
(Inhaled Salbutamol 400 mcg) and one set was acquired after. All images were registered for 29 
voxelwise comparison. Regional treatment response, ǻR(r), is calculated as the difference in 30 
regional gas distribution (R(r) = ratio of inhaled gas to total volume of a voxel when normalized for 31 
lung inflation volume) before and after intervention. A voxelwise activation threshold from the 32 
variability of the baseline images was applied to ǻR(r) maps. The summed global TRM (ǻRnet) was 33 
then used as global lung index for comparison with metrics of bronchodilator response measured 34 
using spirometry and the global imaging metric, percentage ventilated volume (%VV). 35 
Results: ǻRnet showed significant correlation (p<0.01) with changes in FEV1 (r=0.70), FVC 36 
(r=0.84) and %VV (r=0.56). A significant (p<0.01) positive treatment effect was detected by all 37 
metrics, however ǻRnet showed a lower inter-subject coefficient of variation (CV=64%) than all of 38 
the other tests (CV99%).  39 
Conclusions: TRM provides regional quantitative information on changes in inhaled gas ventilation 40 
in response to therapy. This method could be used as sensitive regional outcome metric of novel 41 
respiratory interventions. 42 
 43 
Online supplemental material is available for this article. 44 
  45 
 INTRODUCTION 46 
Lung function tests such as spirometry are widely used to clinically assess airflow obstruction and 47 
its reversibility and indices such as forced expiratory volume in 1 second (FEV1) are commonly 48 
accepted outcome measures in the assessment of therapies for obstructive lung disease. These 49 
techniques, whilst established in respiratory medicine, assess the lungs as one unit with limited 50 
sensitivity to regional ventilation changes (1). Imaging as a diagnostic tool can provide regional 51 
insight into alterations of both structure and function of the lungs and is increasingly being used as 52 
an outcome measure in the early phase evaluation of respiratory therapeutics (2). In particular, 53 
regionally specific therapies such as bronchial thermoplasty in asthma (3), endobronchial valve 54 
therapy (4) and lung volume reduction surgery in COPD (5) require regional information to assess 55 
the efficacy of intervention. Previous studies have used CT and computational fluid dynamics 56 
derived markers of airflow to assess functional changes after bronchodilator therapy (6). 57 
Nevertheless, those methods rely solely on models of ventilation inferred from structural CT images 58 
acquired at different levels of inspiration and repeated use of ionizing radiation which could be 59 
detrimental in particular in paediatric studies.  60 
Functional lung imaging using hyperpolarized (HP) gas MRI provides images of lung ventilation in 61 
3D in a short breath-hold. HP 3He MRI has been shown to be a sensitive measure of ventilation 62 
heterogeneity in asthma (7, 8). While numerous metrics have been derived to describe ventilation 63 
heterogeneity from both HP 129Xe and 3He images using texture based methods like feature analysis 64 
or clustering methods such as k-means (9-12) efforts have been focused on cross-sectional 65 
assessment of cohorts. Longitudinal studies and therapy assessment have focused on the global 66 
outcome measure from HP 3He images in particular percentage ventilated volume (%VV) or its 67 
counterpart the percentage defect volume (7, 13). While %VV has been shown to correlate with 68 
spirometry in asthma (14, 15), the method is limited by the binary classification of ventilated versus 69 
non-ventilated lung regions sacrificing much of the richness of the regional information on lung 70 
 ventilation heterogeneity present in the images. There is therefore a need for imaging metrics that 71 
fully explore the regional sensitivity of these high-resolution images of lung function to assess 72 
success of intervention.  73 
Treatment Response Mapping (TRM) is introduced as a novel technique to provide regional 74 
quantitative information on changes in lung ventilation in response to therapy and is 75 
demonstrated in an asthma cohort by measuring bronchodilator response.  76 
 77 
Material and Methods 78 
The study was approved by the national research ethics committee, and written patient consent was 79 
obtained. All data were acquired between February 2012 and June 2013 and the study was funded 80 
in parts by Novartis. One author (R.K.) is an employee of Novartis. The authors not employed by 81 
Novartis had full control of the data and the information submitted for publication. 82 
 83 
Study Population and Design 84 
20 patients (10/10, female/male) diagnosed with moderate-to-severe asthma (Global Initiative for 85 
Asthma (GINA) step 2 ± 5 (16)), were studied in this retrospective analysis. Patients age range was 86 
21-73 years. Patients were tested for response to bronchodilator (400mcg Salbutamol) with HP gas 87 
ventilation MR imaging and with spirometry. Patient demographics and results from pulmonary 88 
function tests are shown in Table 1. 89 
 90 
MRI Data Acquisition 91 
Prior to the imaging acquisition visit, participants refrained from using any short acting 92 
bronchodilators for at least six hours. Patients were then imaged in a supine position on a clinical 93 
1.5 T MRI scanner (GE HDx, Milwaukee, WI, USA) with a dedicated MR 3He RF coil. 1H MRI 94 
 was performed with the system¶s body coil. Each image was acquired upon inhalation of 1 liter of 95 
gas from a Tedlar bag (350 ml HP 3He mixed with 650 ml N2) from functional residual capacity. 96 
Prior to scanning, subjects were trained in the breathing manoeuvre. Three ventilation MRI scans 97 
were performed in separate breath-holds; two at baseline within 5 minutes of each other, then an 98 
additional scan 20 minutes after bronchodilator to assess short-term airway responsiveness (17) 99 
(Figure 1). Each breath-hold scan consisted of: (1) functional images (HP 3He ventilation, 100 
resolution=3x3x10mm, duration=9s) and (2) structural images (1H anatomy, 101 
resolution=3x6x10mm, duration=4s). To switch between 3He and 1H MR-imaging the scanner 102 
required ~3-5s leading to a total breath-hold duration of under 18 seconds in all cases. Since both 103 
functional and structural images are acquired back-to-back during a single breath-hold, they are 104 
intrinsically co-registered (18).  105 
 106 
Image processing algorithm for Treatment Response Mapping (TRM) 107 
 108 
Structural proton images were first registered between the different time points and the resulting 109 
transformation was applied to the same breath-hold 3He ventilation images (19). This avoided the 110 
registration of the 3He ventilation images being influenced by regional changes of gas distribution 111 
between scans (see online supplementary material). Then images were segmented to extract the 112 
ventilated lung volume using ScanIP (Simpleware Ltd., Exeter, UK).  113 
Regional ventilation was then calculated from image intensity for each dataset. Ventilation as 114 
regional gas distribution in the lung is quantified by conversion of image intensity to the volume 115 
fraction occupied by the inhaled tracer gas in each voxel, this requires knowledge of voxel volume 116 
(Vvoxel) and inhaled gas volume (Vbag) as described by Tzeng et al. (10):  117 
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 Where I (r) is the regional image intensity at position r(x,y,z), Itot the integrated image intensity of 119 
all ventilated areas in the image. R'(r) is the resulting regional gas volume fraction in each voxel. 120 
For example, in the trachea directly after inhalation the gas composition is usually the same as that 121 
inhaled from the bag and hence R' = 1. 122 
In order to compare R'(r) between datasets, the differences in gas dilution of the tracer gas in the 123 
ventilated airspaces have to be taken into account. Following intervention airway opening/closure 124 
will likely result in differences in ventilated lung volume. These variations can cause dilution of the 125 
tracer gas concentration when it is inhaled in the same dose from breath to breath. The ventilated 126 
lung volume after treatment (VLTx) was chosen as the reference point and the normalized gas volume 127 
fraction R was computed as follows: 128 
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Where VL is the ventilated lung volume calculated from the image of interest. Equation 2 assumes 130 
that regional gas concentration scales uniformly with lung volume changes across all voxels in the 131 
lungs.  132 
The difference of gas volume fraction, ǻR(r), before and after intervention is then calculated for all 133 
positions (r) in order to quantify TRM. ǻR(r) is in effect the regionally measured redistribution of 134 
the gas mixture when inhaling identical doses before and after intervention. Like R(r), the TRM, 135 
ǻR(r) is a gas volume fraction, which measures the size and direction of ventilation change due to 136 
intervention. The major airways were excluded, as they do not contribute to gas exchange and can 137 
be expected to be fully ventilated in each breath. To account for ventilation changes related to 138 
physiological baseline variability from scan-to-scan, a voxel-wise baseline variability map, ǻRB(r), 139 
is calculated as the standard deviation of the differences in gas volume fraction R(r) between the 140 
two (filtered) baseline scans. ǻR(r) is set to zero (no effect) for voxels whose ŇǻR(r)Ň  ŇǻRB(r)Ň 141 
and is displayed as white voxels. For remaining voxels, a positive ǻR(r) (improvement in local 142 
ventilation) is shown with a green color scale and a negative ǻR(r) (reduction in local ventilation) 143 
 with a red color scale. In addition, a global value for net treatment response over the whole lungs, 144 
ǻRnet, was calculated: 145 
¦ ' '
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ǻRnet is summed over the lung volume and can be expressed as the percentage (of the inhaled gas 147 
mix =1 liter) or alternatively in ml as the volume of the gas dose that is delivered to newly 148 
ventilated regions of the lung following inhalation of a l liter dose. We emphasise that expression of 149 
ǻRnet in ml is not to be confused with the volume of the lungs that opens up in response to the 150 
bronchodilator, instead it is the amount of the tracer gas (from a 1 liter total inhaled dose), that 151 
reaches newly ventilated lungs. For an inhaled gas mix of 1 liter a theoretical redistribution of 152 
ǻRnet=100% or +1liter would therefore mean a complete redistribution of all inhaled gas in 153 
previously non- or little-ventilated regions. The metric quantifies the sum of regional gas re-154 
distribution as result of the same dose inhaled before and after an intervention. 155 
Accordingly, the global positive and negative change can be calculated by taking only positive or 156 
negative ǻR(r) into account. An analysis of error propagation related to these steps of calculation of 157 
TRM is presented in the online supplement.  158 
 159 
Percentage ventilated volume 160 
%VV was calculated as the ratio of lung ventilated volume (from segmented 3He ventilation 161 
images) to the total volume of the lung in the thorax (from segmentation of the 1H image) as 162 
described previously (18).  163 
 164 
Spirometry 165 
Spirometry was performed with a rolling seal Vitalograph spirometer (Vitalograph, Buckingham, 166 
UK) before and 20 minutes after bronchodilator inhalation according to ATS/ERS guidelines (20). 167 
A minimum of three acceptable FVC manoeuvres were performed and the highest FEV1 and FVC 168 
 of the acceptable curves were recorded. Percent predicted values were calculated as described in 169 
(21). All pre-bronchodilator tests were performed after all bronchodilators had been withheld for at 170 
least six hours. 171 
 172 
Statistics  173 
Statistical analysis was performed using GraphPad Prism (GraphPad Software Inc., San Diego, CA, 174 
USA). All datasets were first tested for normality XVLQJD'¶$JRVWLQR-Pearson omnibus normality 175 
test. Significance of treatment effect was tested using a paired t-test or in the case of a non-normal 176 
distribution the Wilcoxon signed rank. The probability that the null hypothesis (H0 = no treatment 177 
effect is found) can be rejected was tested (for p<0.05 H0 rejected). Values are reported as median ± 178 
interquartile range (25th-75th quartile). &RUUHODWLRQVZHUHFDOFXODWHGXVLQJ3HDUVRQ¶VUcorrelation 179 
6SHDUPDQ¶VFRUUHODWLRQLQFDVHRInon-normality) and the correlation coefficient and significance 180 
level of correlation (p-value) are reported.   181 
 RESULTS 182 
An overview of results from the global MRI metrics (ǻRnet, %VV) and lung function test measurements 183 
(FEV1, FVC) are presented in Table 2 (details of each patient in Table E2). TRM indicated an overall 184 
positive effect of the bronchodilator in agreement with other metrics and the p-values of paired t-tests are 185 
shown in Table 2. An average inter-subject baseline variability ǻRB of 4.74%±4.68% was found. Example 186 
3He ventilation images and the resulting ǻR maps from Patient 2 are shown in Figure 2. 3D renders of TRM 187 
from 4 more patients are shown in Figure 3. Figure 4 shows correlation of ǻRnet with changes in the other 188 
metrics evaluated: %VV r = 0.56 (p = 0.01), FEV1 r = 0.70 (p < 0.01) and FVC r= 0.84 (p<0.01). ǻRnet and 189 
FEV1/FVC did not correlate significantly. The inter-subject coefficient of variation (CV) of ǻRnet was 64% 190 
which is much lower than the CV of %VV and spirometry (both 99%). Figure 5 shows the changes as 191 
assessed by all methods for each individual subject and their collective median (interquartile range). 192 
193 
 DISCUSSION 194 
Treatment response mapping (TRM) of changes in lung ventilation in response to therapy is 195 
demonstrated here with pre and post bronchodilator imaging in a cohort of asthma patients. The 196 
effects of bronchodilator are typically clinically assessed with spirometry, airway resistance or 197 
static lung volume measurement. While being quick and easy to repeat, regional changes in lung 198 
ventilation and airway opening/closing are not accessible with these methods. This is likely to 199 
reduce the sensitivity of these clinical tests to subtle but still clinically significant changes in 200 
ventilation in particular when the treatment is focused on a small lung region (e.g. 201 
bronchothermoplasty or endobronchial valves). Imaging as a diagnostic tool can provide regional 202 
insight into alterations of both structure and function of the lung. Airway wall measurements and 203 
models of lobar ventilation change from inspiratory and expiratory computed tomography (CT) 204 
have both been proposed as image based outcome measures in asthma (6), but the repeated 205 
exposure to ionizing radiation is an issue. HP gas MRI directly measures functional information 206 
from the lungs without ionizing radiation and TRM is a potentially powerful tool for longitudinal 207 
and paediatric studies. Previously, oxygen enhanced MRI has been used to measure changes 208 
induced by bronchodilator and corticosteroids (22). However, it is unclear to what extent this 209 
represents changes in ventilation as signal changes are caused by interaction of protons with O2 210 
dissolved in tissue and blood (23). 211 
Signal intensity from hyperpolarized gas MR images is proportional to the distribution of inhaled 212 
tracer gas in the lung and is therefore a direct measure of ventilation. The TRM method 213 
demonstrated here uses this relation to regionally quantify the magnitude of ventilation changes.  214 
The inherent baseline variability of the images from scan-to-scan without any intervention is also 215 
taken in to account in the algorithm and defines a voxel-ZLVHWKUHVKROGIRUµWUHDWPHQWUHVSRQVH¶. 216 
 This is important as it has been previously shown that originally non-ventilated regions of the lung 217 
can change size and position on the same day in asthma patients without intervention (13). 218 
 219 
One of the most striking findings was the close correlation of FVC and FEV1 with global TRM 220 
metric ǻRnet. The fact that imaging and spirometry were not performed on the same day represents a 221 
limitation of this study and might explain why the correlations between spirometry and ǻRnet are 222 
not stronger. Although all of the tested metrics showed a significant effect of the bronchodilator 223 
(p<0.01), the largest changes were found from ǻRnet (Figure 5). The inter-subject coefficient of 224 
variation of ǻRnet was also smaller (64%) than for the other metrics (. 225 
Some improvements in FVC were high (39% for Patient 2) and might reflect recruitment of air 226 
spaces due to decreased gas trapping, an assumption that is supported by increases in %VV (5.8% 227 
for Patient 2) in most patients. The weaker correlation (r = 0.56) of ǻRnet with changes in %VV 228 
supports the assumption, that changes in ventilation are not only a result of a net increase in viable 229 
ventilated airspace volume, but also reflect changes in heterogeneity of the magnitude of the 230 
ventilation which is regionally elucidated with the TRM method.  231 
In patients with a limited spirometric response (<12%) to bronchodilator, TRM effectively 232 
distinguishes regions of the lung with an increase in ventilation from regions demonstrating reduced 233 
ventilation. This lends some regional evidence to the possibility that bronchodilators are not always 234 
effective and can be potentially detrimental in selected regions of the lung in asthma. Similar 235 
observations have been reported in other imaging biomarker studies (22). Nevertheless, negative 236 
ǻR(r) can result from two other mechanisms; while a degradation of ventilation is observed in 237 
practice in some lung regions after treatment, other regions of negative ǻR(r) might result from 238 
initially hyperventilated regions of lung that were perhaps compensating for obstruction elsewhere, 239 
then returning to more even levels after bronchodilator application. Understanding of physiological 240 
 mechanism and phenotyping these µUHGUHJLRQV¶of worsened ventilation warrants further 241 
investigation.  242 
In conclusion, TRM is able to complement the current techniques for regionally quantifying 243 
changes in ventilation in the lungs. The future clinical potential of the method lies in determining 244 
the regional response of the lungs to new therapies where established lung function tests do not 245 
provide sensitive enough outcome measures. This sensitivity to local changes in ventilation could 246 
also result in a reduction of patient cohort numbers required to confirm success of a treatment in a 247 
clinical trial. 248 
Current limitations of the technique are the prolonged breath-hold required for image acquisition 249 
and the requirement for HP gas MR-imaging infrastructure for effective delivery in a clinical 250 
setting. Recent advances may help overcome this barrier in years to come as the technique may also 251 
be directly applicable to ventilation images acquired using other gases to image lung function such 252 
as HP 129Xe or 19F fluorinated gases like Perfluoropropane (24, 25). 253 
 254 
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 Tables 319 
Table 1. Overview of demographics and results from pulmonary function tests in 20 asthma 320 
patients. All values presented as mean (± standard deviation), measured before application of the 321 
bronchodilator. Spirometry was performed with a rolling seal Vitalograph spirometer (Vitalograph, 322 
Buckingham, UK) according to ERS/ATS guidelines (20).  323 
 
Study participants 
(n=20) 
Age (years) 51±12 
Sex (female/male) 10/10 
Height (m) 1.66±0.07 
Weight (kg) 82±15 
BMI (kg/m2) 30±5 
GINA 4.10±0.68 
Pack years 0.62±1.91 
RV (L) 2.78±1.18 
TLC (L) 6.23±1.54 
FEV1(%pred), mean±SD (range) 71±28, (27-122) 
FVC(%pred), mean±SD (range) 92±22, (54-138) 
FEV1/FVC(%pred), mean±SD (range) 75±17, (31-83) 
BMI = body mass index, %pred = percent predicted, GINA = global initiative for asthma 324 
classification (16), pack years = lifetime tobacco exposure, 1 pack year defined as 20 cigarettes a 325 
day for a year; RV = residual volume, TLC = total lung capacity, FEV1 = forced expiratory volume 326 
in 1 second; FVC = Forced vital capacity. Predicted values calculated using GLI equations (21). 327 
Horn et al.  17 
Table 2. Summary of outcome measures used to assess treatment response including the net 328 
treatment effect (ǻRnet.) All values expressed as median (interquartile range: 25th-75th quartile). 329 
Patient specific values are shown in Table E2 (online) alongside scatter plots in Figure E1. 330 
  331 
Horn et al.  18 
Outcome metric Treatment: Bronchodilator (BD) 
Absolute measurement preBD postBD 
paired t-test 
p-value 
Difference 
(postBD-preBD) 
FEV1(%pred) 72(44-96) 79(58-100) 0.0002 6.3(4.5-13) 
FVC (%pred) 85(76-110) 93(85-120) 0.004 5.2(1.9-8.3) 
FEV1/FVC(%) 68(48-73) 88(65-91) <0.0001 3.6(2.4-5.5) 
%VV (imaging) 88(83-94) 93(90-97) 0.0009§ 3.5(0.2-5.7) 
Differential measure positive ǻRnet negative ǻRnet 
paired t-test 
p-value 
ǻRnet 
ǻRnet (%) 20(16-26) 9(7-11) <0.0001§ 11(6.6-14) 
ǻRnet (ml) 210(160-260) 92(71-110) <0.0001§ 110(66-140) 
*CV = coefficient of variation as ratio of standard deviation to mean of treatment effect. 332 
§
 
non-normally distributed data, Wilcoxon signed rank test was used. Figure legends 333 
Figure 1: Image processing workflow from left to right: 3D image sets (proton and HP gas 334 
ventilation image within a single breath-hold) are acquired twice at baseline to calculate baseline 335 
variability. 20 minutes after bronchodilator application another 3D set is acquired. The difference 336 
between pre-and post-bronchodilator images are plotted as treatment response ǻR(r) maps and 337 
compared to a regional treatment activation threshold from baseline variability, ǻRB(r). The dataset 338 
is from a 54-year-old male, Patient 2. 339 
Figure 2: Examples of coronal treatment response maps (top row), MR ventilation images at 340 
baseline (middle row) and post bronchodilator inhalation (bottom row), from Patient 2 (54 years, 341 
Horn et al.  19 
male). The positive ǻRnet= 35.1% is compared to the negative ǻRnet= 5.5% resulting in a total ǻRnet 342 
of +29.7%. 343 
Figure 3: Example 3D rendered treatment response maps from 4 volunteers and the corresponding 344 
histograms. 345 
Figure 4: Correlation of ǻRnet from histograms (in %) with changes in (a) percentage ventilation 346 
volume from before and after treatment (ǻ%VV) with D6SHDUPDQ¶V r = 0.56, P = 0.01, (b) 347 
Correlation of ǻRnet with changes in FEV1 from treatment (ǻFEV1ZLWKD3HDUVRQ¶Vr = 0.70, P = 348 
0.004 and (c) Correlation of ǻRnet ZLWK)9&ZLWKD3HDUVRQ¶Vr = 0.84, P <0.001. Dotted lines show 349 
95% confidence intervals.  350 
Figure 5: Comparison of changes from bronchodilator visualizing the data from Table 2. Each plot 351 
shows median ± interquartile range interval including each individual data point. Changes are 352 
expressed as difference in percent predicted (FEV1/FVC, FVC, FEV1), difference in %VV before 353 
and after treatment and percent ǻRnet. The plot shows that the treatment effect found from ǻRnet is 354 
greater on average and the standard deviation is smaller than those of spirometric indices. 355 
  356 
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Abbreviations used: 357 
%VV Percentage Ventilated Volume 358 
ǻRB Baseline variability; change in ventilation fraction in each voxel between the two 359 
images acquired at baseline (before application of the bronchodilator)  360 
ǻR Treatment Response; change in ventilation fraction in each voxel between images 361 
acquired before and after application of the bronchodilator 362 
COPD Chronic obstructive pulmonary disease 363 
CT Computed tomography 364 
FEV1 Forced expiratory volume in 1 second 365 
FVC Forced vital capacity 366 
HP hyperpolarized 367 
MRI Magnetic resonance imaging  368 
ǻRnet net treatment response over the whole lung as a result of repeated inhalation of 1 liter 369 
of the gas mix containing the hyperpolarized 3He gas; expressed in ml and as percent 370 
of the inhaled gas volume (1liter) 371 
PFP Perfluoropropane gas is a fluorinated gas (used for lung imaging) 372 
TRM Treatment response map 373 
VH Ventilation heterogeneity 374 
 375 
 376 
 377 
 378 
 379 
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e-Appendix 380 
Details of MR image acquisition 381 
Patients were imaged using a whole-body clinical 1.5 T MRI scanner (GE HDx, Milwaukee, WI, 382 
USA) with a quadrature transmit-receive vest coil tuned to 48.65MHz for 3He imaging (Clinical 383 
MR Solutions, Brookfield, WI, USA) and the quadrature transmit-receive body coil for proton 384 
imaging. Patients were trained in the breathing manoeuvre outside the MR scanner before scanning 385 
and once more inside the MRI scanner before administration of the HP 3He. 386 
 387 
Helium was polarized on site to approximately 25% using a rubidium spin exchange polarizer (GE 388 
Healthcare, Amersham, UK).  Patients inhaled 350 ml 3He mixed with 650 ml N2 from a Tedlar bag 389 
(Jensen Inert Products, Coral Springs, Florida, USA) from functional residual capacity (FRC). 390 
Ventilation (3He) and Anatomical (1H) images were acquired back-to-back during one breath-hold 391 
covering the same volume (1).  392 
Table E1. Summary of imaging parameters. 393 
Scan 
MRI 
Sequence 
Repetition 
time (ms) 
Echo 
time (ms) 
Flip 
angle 
(°) 
Bandwidth  
(kHz) 
Field of view 
(cm) frequency 
x phase 
Matrix size 
frequency x 
phase 
Pixel size (mm) 
frequency x 
phase 
Slice 
thickness 
(mm) 
Ventilation 
(3He) 
SPGR 3.6 1.1 8 62.5 38.4 x 30.7 128x102 3x3 10 
Anatomical 
(1H) 
SSFP 2.4 2.4 50 167 38.4 x 38.4 128x64 3x6 10 
 394 
 395 
 396 
 397 
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 398 
Challenges in calculating treatment response maps 399 
Quantifying regional ventilation changes between longitudinal time-points is a challenge in lung 400 
imaging due to patient re-positioning and differences in lung volume between acquisitions. The 401 
problem of lung volume variation between separate breaths has been highlighted previously (1) in 402 
the calculation of percent ventilated volume (%VV), where acquisition of proton images and 403 
ventilation images in separate breaths has been shown to considerably influence the reliability of 404 
%VV. Here %VV was calculated from ventilation and anatomical images acquired within the same 405 
breath to avoid this problem. When calculating treatment response maps, image registration with 406 
the same breath 1H anatomical images was used to overcome differences in lung volume of 407 
ventilation images acquired at different breath-holds and patient movement between time-points. 408 
This process reduces image registration errors introduced by morphological changes in gas 409 
distribution in the ventilation images that arise from response to treatment. Registration of images 410 
in this way then allows regional comparison of ventilation changes and treatment response mapping 411 
over multiple time points.  412 
Images were acquired with the patient in a similar position within the coil and using the same 413 
sequence parameters each time, allowing a comparison of relative changes in image intensity. It is 414 
acknowledged that lung units with very low ventilation, resulting in a long time constant for gas 415 
wash-in, may not be captured with a single-breath ventilation imaging method (2). 416 
 417 
Error in the calculation of ǻR 418 
The quantification of treatment response is sensitive to the amount of HP gas inhaled. It is assumed 419 
that a total of 1 liter (350ml 3He and 650 N2) is precisely dispensed and fully inhaled. Patients are 420 
trained in the inhalation process before entering the scanner to assure a successful emptying and 421 
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inhalation of the contents of the bag of gas. When dispensing the gas, a typical dispense accuracy of 422 
±25ml in the volume of the bag can be achieved. The contribution of the inhaled bag volume to the 423 
calculation of the local voxelwise ventilation fraction can be derived from Equation 1 of the main 424 
text as follows: 425 
tot
bag
voxel I
V
V
IR  )r()r(
    Eq. E1 426 
where I(r) is the regional image intensity, Vvoxel is the volume of a voxel, Vbag is the volume of the 427 
bag containing the HP 3He mixture (1 liter).  428 
This allows a simple error estimation of how the bag volume Vbag contributes to the error in 429 
voxelwise estimate of fractional ventilation:  430 
%5.2
2
 ¸¸¹
·
¨¨©
§ w w
bag
bag
V
V
R
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    Eq. E2 431 
Thus this results in a propagated error in voxel fractional ventilation of less than 2.5%. As the 432 
treatment response measurement, ǻR (r) is the result of a subtraction of two ventilation fractions 433 
(R(r) from two images) the maximum potential error is compounded to 3.5%. 434 
7KHHIIHFWRILPDJHUHJLVWUDWLRQRQǻR(r) was not investigated. Nevertheless, the above discussion 435 
shows how effects were mitigated and it can therefore be assumed that effects from mis-registration 436 
are negligible.  437 
 438 
Appendix Figures 439 
 440 
Figure E1: Plots of all of the tested methods are shown. Individual plots show each data-point, 441 
median and interquartile range. (a) Net Treatment response (ǻRnet), a significant response to 442 
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bronchodilator treatment was found. Although all methods show significant sensitivity to effects of 443 
bronchodilators, negative ǻRnet is tightly clustered around the mean value of 10% and both groups 444 
(positive and negative ǻRnet) show visibly clearer separation. Positive treatment response (positive 445 
ǻRnet = 20% ± 7%) over the cohort was found to be significantly greater than average negative 446 
treatment response (negative ǻRnet = 10%± 4%) (P<0.0001, CI of median = [8.8-12.4]). (b) %VV 447 
before and after bronchodilator application. Significant response to bronchdilator treatment was 448 
found (p<0.01). Percentage ventilated volume (%VV) also showed significant increase (P<0.001, 449 
CI of median = [0.41, 5.4]) after bronchodilator application. (c) FEV1 before and after 450 
bronchodilator application, a significant response to bronchdilator treatment was found (p<0.01). 451 
FEV1 also increased significantly (P=0.0001, CI of median = [5.1, 12.2]) in response to 452 
bronchodilator inhalation as well as FVC (P=0.0001, CI of median= [2.8, 8.0]). (d) FVC before and 453 
after bronchodilator application. Significant response to bronchdilator treatment was found 454 
(p<0.01).  455 
 456 
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Table E2: An overview of all outcome measure from each individual asthma patient imaged.  457 
 458 
Pre-PostBD FEV1 Treatment response mapping Baseline Variability
BMI GINA %VV VV [ml] FEV1% FVC% %VV VV [ml] FEV1% FVC% FEV1 change[ml] ƉŽƐŝƚŝǀĞEĞƚ ?ȴZTR[ml] ƉŽƐŝƚŝǀĞEĞƚ ?ȴZTR[%] ŶĞŐĂƚŝǀĞEĞƚ ?ȴZTR[ml] ŶĞŐĂƚŝǀĞEĞƚ ?ȴZTR[%] EĞƚ ?ȴZTR[ml] EĞƚ ?ȴZTR[%] DĞĂŶȴRB[%]
38.5 4 79.62 3518 41.39 75.47 91.54 3552 57.95 88.88 400 222.9 22.29 79.38 7.94 143.5 14.35 9.33
38.7 5 86.27 4496 32.74 54.34 92.05 4669 61.11 94.26 650 351.1 35.11 54.45 5.45 296.7 29.67 5.38
34.6 4 87.21 3208 70.40 83.20 89.54 3302 76.46 86.72 130 178.6 17.86 83.49 8.35 95.11 9.51 5.30
39.6 5 92.95 3297 73.71 85.88 92.54 3442 82.07 91.39 220 158.2 15.82 101.9 10.19 56.37 5.64 6.63
25.3 4 93.06 3363 53.76 62.97 96.20 3301 69.85 77.13 790 266.7 26.67 67.87 6.79 198.9 19.89 3.48
29.5 4 94.78 4327 72.38 83.95 93.46 4517 76.19 81.98 1130 122.6 12.26 125.8 12.58 -3.204 -0.32 4.72
25.7 4 94.10 4766 96.81 114.07 97.95 5228 101.86 115.60 440 137 13.70 79.13 7.91 57.9 5.79 3.70
24.8 5 88.35 3959 95.22 118.33 95.53 4245 107.91 122.91 120 196.8 19.68 85.5 8.55 111.3 11.13 3.06
32.9 4 94.14 4928 114.21 137.97 96.08 4305 126.42 142.80 190 243.9 24.39 141.7 14.17 102.2 10.22 2.47
29 4 81.26 4746 43.52 94.59 78.43 4553 50.72 101.22 280 326.2 32.62 99.2 9.92 227 22.70 5.15
29.2 2 82.23 5070 71.87 100.39 91.36 4992 103.06 121.00 370 279.4 27.94 67.15 6.72 212.3 21.23 3.93
25.8 5 57.51 3498 41.40 69.50 60.56 3562 34.16 67.36 230 155.1 15.51 53.71 5.37 101.4 10.14 10.77
23.2 4 73.88 4224 27.28 68.65 79.15 4674 31.18 71.89 1150 175.5 17.55 65.61 6.56 109.9 10.99 2.49
30.2 3 97.17 4519 100.36 105.45 97.58 4098 106.11 105.91 -180 113.5 11.35 96.29 9.63 17.22 1.72 3.52
24.7 4 94.14 4186 121.82 123.75 98.35 5214 127.05 126.54 130 292.6 29.26 181.1 18.11 111.4 11.14 4.91
28.8 4 87.55 3314 77.69 77.88 95.26 3133 81.98 85.87 210 223.6 22.36 117.2 11.72 106.4 10.64 4.68
22.2 4 99.10 3478 100.76 114.38 99.28 3711 100.76 110.37 110 120.8 12.08 96.87 9.69 23.92 2.39 1.93
31.1 4 92.54 3526 84.33 108.82 97.93 4291 90.04 115.11 150 215.6 21.56 91.74 9.17 123.9 12.39 6.04
36.6 4 84.79 3775 51.48 79.10 90.19 3934 59.55 85.22 0 208 20.80 90.97 9.10 117 11.70 4.88
21.9 4 87.11 4260 46.76 82.01 85.10 3966 53.20 90.34 190 201.8 20.18 113.7 11.37 88.18 8.82 2.34
PreBonchodilator PostBronchodilator
459 
 460 
 461 
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